CRISPR Therapeutics (CRSP) Tops Q4 EPS by 79c
Tweet
Share
E-mail
Get Alerts CRSP Hot Sheet
Join SI Premium – FREE
CRISPR Therapeutics (NASDAQ: CRSP) reported Q4 EPS of ($0.44), $0.79 better than the analyst estimate of ($1.23). Revenue for the quarter came in at $35.69 million versus the consensus estimate of $7.63 million.
For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
- Primoris cuts 2026 outlook on renewables cost overruns, COO exits
- Avis Budget Group reaches $650M settlement with Pentwater Capital
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
